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The neuronal ceroid lipofuscinoses (NCLs, Batten disease) are a group of fatal recessively inherited neurodegenerative diseases of humans and
animals characterised by common clinical signs and pathology. These include blindness, ataxia, dementia, behavioural changes, seizures, brain
and retinal atrophy and accumulation of fluorescent lysosome derived organelles in most cells. A number of different variants have been suggested
and seven different causative genes identified in humans (CLN1, CLN2, CLN3, CLN5, CLN6, CLN8 and CTSD). Animal models have played a
central role in the investigation of this group of diseases and are extremely valuable for developing a better understanding of the disease
mechanisms and possible therapeutic approaches. Ovine models include flocks of affected New Zealand South Hampshires and Borderdales and
Australian Merinos. The ovine CLN6 gene has been sequenced in a representative selection of these sheep. These investigations unveiled the
mutation responsible for the disease in Merino sheep (c.184C>T; p.Arg62Cys) and three common ovine allelic variants (c.56A>G, c.822G>A
and c.933_934insCT). Linkage analysis established that CLN6 is the gene most likely to cause NCL in affected South Hampshire sheep, which do
not have the c.184C>T mutation but show reduced expression of CLN6 mRNA in a range of tissues as determined by real-time PCR. Lack of
linkage precludes CLN6 as a candidate for NCL in Borderdale sheep.
© 2006 Elsevier B.V. All rights reserved.Keywords: NCLs; Batten disease; CLN6; Sheep model; Lysosomal storage disease; Neurodegeneration1. Introduction
The neuronal ceroid lipofuscinoses (NCLs, Batten disease)
are a group of fatal inherited lysosomal storage disorders
affecting an estimated 1 in 12,500 children worldwide [1].
Affected children start life normally but then develop
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doi:10.1016/j.bbadis.2006.09.004mental and motor deterioration as neurodegeneration pro-
gresses. At present there are no effective therapies and life
expectancy is reduced to between 7 years of age and early
adulthood, depending on the form of the disease. Rare cases
with adult onset and a slower disease progression have been
reported [2].
All forms share two definitive hallmarks; progressive brain
atrophy and the accumulation of fluorescent lysosome derived
organelles (storage bodies) in neurons and most other cells
throughout the body. Retinal degeneration is also a common
feature. The clinical features, characteristic pathologies and
ultrastructure of each form have been well described, along
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Different mutations in at least seven genes underlie the
human NCLs (www.ucl.ac.uk/ncl). Better understanding of
the genetic basis of these diseases has led to increased
awareness, improved diagnosis and an increase in the number
of cases reported. Unfortunately the identification of these
disease genes has not yet provided a breakthrough in the
understanding of the disease mechanisms. Five genes (CLN3,
5, 6, 8 and CTSD) encode novel proteins and knowledge of
their functions is limited [2–5]. Two other genes (CLN1 and
CLN2) code for the known lysosomal enzymes, PPT1 and
TPP1 [2,3].
Animal models in which all affected individuals have the
same mutation are particularly valuable tools for determining
the pathophysiology of disease and for validating therapeutic
strategies. A number of naturally occurring and transgenically
modified animal models have been described caused by
mutations in genes homologous to CLN1,2,3,5, 6 and 8 (NCL
resource: (www.ucl.ac.uk/ncl). Another form of NCL caused by
a mutation in cathepsin D (CTSD) has recently been
characterised in humans [5] as well as sheep, dogs and mice
[6–8].
Naturally occurring large domestic animal models are
particularly valuable because their brain size and structure is
larger and more human-like than that of rodents and their longer
life expectancy allows for investigations of the long-term effects
of treatments. In general the clinical progression in larger
animals more closely resembles that in humans. Domestic
production animals have the additional advantages of being
economic to maintain, have been bred for easy management and
a high level of expertise in reproductive technology and
veterinary care is available for them.
Best characterised of the NCL animal models is the CLN6
form in New Zealand South Hampshire sheep, first diagnosed
three decades ago [9–11]. In a number of ways these sheep are a
prototype of the NCLs. They develop clinical symptoms
between 10 and 14 months of age, notably blindness as a result
of atrophy of the occipital cortex and loss of photoreceptors in
the retina [12]. Specific lysosomal storage of subunit c of
mitochondrial ATP synthase was first observed in them [13–
15], and subsequently in the CLN2, CLN3, CLN5, and CLN8
human forms [15,16], with infantile (CLN1) and congenital
(CTSD) forms being the exception [5,15,17]. Subunit c storage
has since been confirmed in most animal forms of NCL,
including most mouse [18–20] and canine forms [21], Devon
cattle [22] and the recently described disease in horses [23].
Recent studies of neuropathological changes in brains from
presymptomatic CLN6 affected South Hampshire sheep [24],
beginning prenatally [25], revealed precocious activation of
glial cells long before any apparent neurodegeneration and
while the brain is being formed. Activation spread to different
cortical areas in the order of development of associated
symptomology. Generalised neurodegeneration followed [24].
Up-regulation of manganese superoxide dismutase (Mn-SOD)
found in sheep and human tissue and cells affected with CLN6
NCL [26] may be part of the activation cascade. In contrast,
storage body accumulation was more evenly spread acrossregions at all ages, suggesting that neurodegeneration and
storage body accumulation are independent manifestations of
the disease [24].
This perinatal onset of a complex cascade of glial activation
suggests that glia may be central to NCL pathogenesis but it is
not clear when this cascade becomes fatally damaging to
neurons. A chronic inflammatory response is damaging to
neurons [27–29], so it is surprising how long the development
of the affected sheep brains follows a normal path [25].
Traditionally glial activation in neurodegenerative conditions
has been assumed to be initiated by dying neurons or some
ligand such as abnormally deposited β-amyloid protein [29,30],
but these studies indicate a more central role and that
suppression of inflammation may be a valuable adjunct to
other therapies [25].
Positional cloning studies localised the gene for the South
Hampshire disease to a region on sheep chromosome 7
homologous with the 15q21–23 human region, which contains
the human CLN6 gene implicated in variant late infantile NCL
[31–33]. This gene contains 7 exons and encodes a predicted
311 amino acid transmembrane protein of unknown function.
The analogous murine gene contains the mutation causing
disease in nclf mice [32]. Independent cell biology and
biochemical studies in affected humans and sheep indicated
that CLN6 encodes an endoplasmic reticulum resident protein
[34,35], the absence of which may affect pre-lysosome
vesicular transport as indicated by its affect on arylsulfatase A
endocytosis via the plasma membrane 300 kDa mannose-6-
phosphate receptor [34].
Australian Merino sheep were diagnosed with NCL [36] and
a homozygosity mapping approach mapped the disease to the
same region on sheep chromosome 7 identified in South
Hampshire sheep [37]. Since the disease aetiology in these
sheep is very similar to that in the South Hampshires it was
considered that the mutation would be shared. Another
occurrence of ovine NCL was diagnosed in New Zealand in
Borderdale sheep [38]. In this case the pathology and disease
course were different enough to suspect a different genetic
cause. Research flocks have been established for the Borderdale
[38] and Merino sheep [36].
Below we report the molecular genetic characterisation of
the ovine CLN6 coding sequence, unveil the mutation
responsible for the disease in the Merino sheep, describe
reduced expression of CLN6 in the affected South Hampshire
sheep and exclude CLN6 as a candidate gene for the disease in
Borderdale sheep.2. Materials and methods
2.1. Animals
Animals were mated in single pairs or by artificial insemination (AI) so that
the parentage of offspring is known. They were maintained under standard New
Zealand or Australian pastoral conditions on university research farms with
adjacent animal hospital facilities. All procedures accorded to NIH guidelines
and the New Zealand Animal Welfare Act (1999), or the NSWAnimal Research
Act (1985) and the Australian Code of Practice for the Care and Use of Animals
for Scientific Purposes 7th Edition (NH and MRC 2004). Some affected lambs
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[39].
The clinical progression of this disorder was previously characterised for
each ovine model [9–12,36,38]. An unrelated breed of sheep, the Coopworth,
was used for control samples in the case of the South Hampshire and Borderdale
research. Unaffected Merino sheep were obtained from an unrelated flock at the
University of Sydney, as well as from the original flock and the current NCL
research flock. Sheep were classified as unaffected on the basis of a lack of
clinical phenotype and/or histopathology.
2.2. Nucleic acid extraction
Genomic DNA was extracted from blood of clinically affected and normal
Merino, South Hampshire and Borderdale sheep and Coopworth control sheep
using the QIAamp DNA mini kit (Qiagen, Hilden, Germany). Three bacterial
artificial chromosome (BAC) clones (35C9, 270H8 and 35B7) were kindly
provided by Dr. Daniel Vaiman (INRA, Jouy-en-Josas, France) after PCR
screening of an ovine BAC library [40] with CLN6 specific primers. Sequence
screening of an ovine EST database revealed an EST clone containing CLN6
sequence that was purchased from Ovita Ltd. (Dunedin, New Zealand). DNA
was extracted from the EST and BAC clones using a Qiagen midi prep kit
(Qiagen).
Total RNAwas extracted from the brain, liver or skeletal muscle of affected,
heterozygous and normal Merino and South Hampshire sheep and from normal
Coopworth sheep, using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). The
total RNA fractions of each sample were converted to cDNA using SuperScript
II reverse transcriptase (Invitrogen) and oligo d(T)15 as primer.Fig. 1. Alignment of the predicted CLN6 polypeptide sequences. A black backgr
(p. Arg62Cys) is indicated, “#”. A human disease causing mutation (p. Arg62His) al
sheep sequences in position 56 (c.56A in Merinos and c.56G in South Hampshires) le
by “1”. A silent c.822G>A substitution is indicated, “2”, and a c.933_934insCTat the
codon 1 amino acid downstream. This polymorphism occurs in affected, carrier and2.3. Sequencing
Both Merino and South Hampshire CLN6 sequencing reactions were
performed on PCR products amplified from cDNA or genomic DNA. PCR
products were separated on agarose gels, excised and purified using the
Perfectprep Gel Cleanup kit (Eppendorf, Hamburg, Germany) before direct
sequencing with the primers used for the PCR amplification. Direct BAC
sequencing was performed using 1.5 μg of purified BAC DNA per reaction.
Sequence reactions were performed using a BigDye terminator v3.1 Cycle
sequencing kit and 5×BigDye v1.1/3.1 Sequencing Buffer (Applied Biosys-
tems, Foster City, CA, USA). The pre-sequencing cleanup of excess dye
terminator was performed with a CleanSEQ Dye-Terminator Removal kit
(Agencout Bioscience Corporation, Beverly, MA, USA) and the samples were
run on a ABI PRISM 3100-Avant Genetic Analyser (Applied Biosystems).
Merino specific sequence was also obtained from PCR products purified by
EXOSAP-IT (Amersham Pharmacia Biotech, Piscataway, NJ, USA) sequenced
using a Sequitherm Excell II sequencing kit (Epicenter Biotechnologies,
Madison, WI, USA) and a LI-COR 4200 sequencer (Lincoln, NE, USA),
incorporating M13 tailed primers [41] and simultaneous bi-directional
sequencing [42].
2.4. Sequence compilation and analysis
Sequences produced were analysed using genescan [43] and aligned using
genedoc [44] to human (Genbank accession number NM_017882), mouse
(Genbank accession number NM_001033175) and dog (Genbank accession
number NM_001011888)CLN6mRNAand protein sequence published onNCBI.ound indicates conserved amino acids. The position of the Merino mutation
so occurs at this position. A SNP between normal Merino and South Hampshire
ading to a amino acid change between the two breeds (p.Gln19Arg) is indicated
terminus of the polypeptide, “3”, adds a C terminal Tyr and shifts the termination
normal individuals.
Fig. 2. Restriction enzyme detection of the c.184C>T substitution in the Merino
(M) sheep. A 151 bp PCR product amplified from the normal allele is cleaved
with HaeIII but the product from the affected allele is not. Animals with the
mutation show an uncut 151 bp product on agarose gels, normal animals two
bands of 50 and 101 bp, and carriers show all three bands.
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Direct DNA test (c.184C>T): PCRs were performed on genomic DNA in
20 μl containing 5 μM of the forward primer 2aF (5′-GCA CAG CTC CGT
CAA GGC-3′) and of the reverse primer I2R2 (5′-CAC AGC TTC ACT CTC
ACC AT-3′), 1×Q buffer (1.5 mM MgCl2) (Qiagen), 200 mM dNTP and 1 U
HotStar Taq DNA polymerase (Qiagen) under the following conditions: 95 °C
15 min; 45 cycles at 95 °C 30 sec, 52 °C 30 sec, 72 °C 1 min followed by 72 °C
1 min. The resulting 151 base pair (bp) PCR products were digested with 0.5 U
HaeIII (New England Biolabs, Ipswich, MA, USA), 3 h at 37 °C and separated
on 4% agarose gels to identify individual genotypes. Normal sheep yielded two
fragments of 101 and 50 bp, carriers three fragments of 151, 101 and 50 bp and
affected sheep only the undigested PCR product of 151 bp (Fig. 2).
Indirect DNA test (c.822G>A): PCRs were performed on genomic DNA as
above using the forward primer 7aF (5′-CTT CAT CCT CTT CAT CTT CAC
CTT-3′) and the reverse primer 7aR (5′-AGG ACT CTATTG GCT GC-3′). The
resulting 251 bp PCR products were digested with 0.5 U HaeII (New England
Biolabs) for 3 h at 37 °C, and the products separated on 4% agarose gels. ‘GG’
sheep yielded two fragments of 117 and 67 bp; ‘GA’ sheep show three fragments
of 184, 117 and 67 bp; and ‘AA’ sheep two fragments of 184 and 67 bp (Fig. 3).
A similar banding pattern was obtained from digestion of PCR products formed
using an alternative forward primer, E7F1 (5′-GTA CCT GGT CAC CGA
GGG-3′). Two-point linkage analysis was performed using Cri-Map [45].
2.6. mRNA analysis
For CLN6 transcript level analysis, CLN6 cDNA was amplified using
primers Ex2-3F (5′-ATA GCCATGCTGGTG TTCC-3′) and Ex3-4R (5′-CAC
CGC TCG ATG AGC TTG AG-3′). GAPDH cDNA was co-amplified using
primers GAPDH-forward (5′-AGG CCA TCA CCA TCT TCC AG-3′) and
GAPDH-reverse (5′-GGC GTG GAC AGT GGT CAT AA-3′) and used as an
internal control. Quantitative real-time PCRs were performed using iQ SYBR
Green Supermix (Bio-rad Laboratories, Hercules, CA, USA) and the iCycler iQ
real-time PCR detection System (Bio-rad Laboratories). The CLN6 mRNA
levels were normalised against the level of GAPDH mRNA in each sample.
For CLN6 exon 5 alternative splicing analysis, CLN6 cDNAwas amplified
using primers Ex4F (5′-AGC ATC CAC CTG GTG GGC GAC TC-3′) and
Ex6R (5′-TGG CAT TGA GCT CTC AGC TTT GGT G-3′). Transcripts
retaining exon 5 generated a PCR product of 249 bp and transcripts lacking exon
5 a PCR product of 193 bp. Full length and truncated CLN6 transcripts were
separated on 2% agarose gels, excised and purified using the Perfectprep Gel
Cleanup kit (Eppendorf) before sequencing as described above.
For the quantitative analysis of the exon 5 splicing variants, CLN6 cDNA
was amplified using primers spanning the exon junctions, ex4–5F (5′-AGA
GACGCT GAT CGA CTC CT-3′) and ex6–7R (5′-GAC CAGGTA CCAGTA
GTA CA-3′) specific for the full length transcript, and primers ex4F-bis (5′-
AGC ATC CAC CTG GTG GGC GAC TC-3′) and ex4-6R (5′-ATG TAC CAG
CGT CTC TGG CT-3′) specific for the splice variant. Quantitative real-time
PCR was performed as described using GAPDH as the internal control.3. Results
The initial ovine coding sequence was determined in an EST
clone identified in an EST library, then confirmed in cDNATable 1
Summary of allelic variation within ovine CLN6 in Coopworth, South Hampshire, M
Coopworth South Hampshire
wt Heterozygous Affecte
c.184C>T (#) CC CC CC
c.56A>G (1) GA or GG Unknown GG
c.822G>A (2) GG or GA GA some AA AA
c.933_934insCT (3) - - or insCT Heterozygous for insertion insCTobtained from unaffected Coopworth and Merino sheep, South
Hampshire and Merino sheep heterozygous for NCL and South
Hampshire and Merino sheep affected with NCL. The coding
sequence was readily determined including the start ATG,
which has been confirmed through multiple sequence align-
ments with other species (human, mice, dog) and sequencing
the ovine EST clone which contained 20 bp sequence up-
stream of the start codon. This cDNA sequence was validated
and exon/intron boundaries identified by sequencing genomic
DNA of affected and control sheep and of a BAC clone
containing CLN6. The ovine coding sequence is 933 bp long
(NM_001040289) and comprises 7 exons. It has an identical
gene structure and 90% sequence homology to human CLN6. A
notable feature in this gene is the high GC content of exon 1,
82% in sheep, which is even higher than the 77% in humans.
The predicted CLN6 polypeptide is highly conserved between
sheep, mice and humans (Fig. 1), with some variation at the N
terminal end as shown in Fig. 1.
Aligning the various ovine CLN6 sequences revealed four
allelic variants in the coding region (Table 1). A c.184C>T
substitution was identified in exon 2 in affected Merino sheep
that codes for a major amino acid exchange (p.Arg62Cys) in the
putative gene product (Fig. 1). The nucleotide substitution
results in the removal of a HaeIII cleavage site and a PCR-
restriction enzyme assay was applied to 135 Merino sheep to
confirm the disease association of the mutation (Fig. 2). All 40
affected Merinos yielded an uncleaved PCR product, all 45erino and Borderdale wild type (wt) and affected sheep
Merino Borderdale
d wt Affected wt Affected
CC TT CC CC
AA AA GG GG
GG some GA AA AA, GG or GA AA, GG or GA
- - or insCT insCT Unknown Unknown
Fig. 3. Restriction enzyme detection of the c.822G>A polymorphism. A 251 bp
PCR product from ‘GG’ sheep cleaved with HaeII results in two bands of 117
and 67 bp shown in 4% agarose gels, ‘GA’ sheep yield three bands of 184, 117
and 67 bp, and ‘AA” sheep two bands of 184 and 67 bp. This polymorphism is
used as an indirect DNA test in the South Hampshire (SH) sheep. Lane 1
contains a size standard with 300, 200 and 100 bp bands visible.
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50 clinically normal animals yielded cleaved DNA, showing
that the mutation segregates with the disease. Linkage analysis
of the Merino flock (n=74) resulted in a LOD score of 10.24
with no recombination (θ=0.00). These results indicate that the
mutation is strongly associated and most likely causative of the
CLN6 form in Merino sheep. This mutation has not been found
in any control or affected South Hampshire or Borderdale
sheep, so it is not the causative mutation in either breed.
A second allelic variant recognised in the coding region of
CLN6 is 111 bases downstream from the 5′ end of exon 7,
where either A or G (c.822G>A) is the third base of a triplet
coding for alanine (Fig. 1). This variation alters a restriction site
for the enzyme HaeII. PCR amplification, enzyme cleavage and
agarose gel separation was used for genotyping in South
Hampshire, Merino and Borderdale sheep (Fig. 3). Linkage
analysis between this marker and the disease in the South
Hampshire sheep, carried out on 85 affected, 187 heterozygous
and 154 control sheep, resulted in a LOD score of 13.3
(θ=0.01) indicating that the mutation is in CLN6 or a gene
extremely close by. The only recombinant animal could be due
to an error in pedigree information, anticipated from the
frequency of mis-mothering in sheep. While all the affected
South Hampshire sheep carry only the A allele, a screen of other
breeds revealed that the A allele is quite common, e.g. 16 out ofFig. 4. CLN6 splice variants. Reverse transcription-PCR amplification of CLN6 betwe
separated on an agarose gel (left panel). Sequencing of the two bands confirmed t
boundaries of each exon.43 sheep tested in the Coopworth control flock were
heterozygous for the allele (P=0.186), yet no NCL affected
individuals have ever been found in this long established flock.
This silent substitution is highly unlikely to be the disease
causing mutation, but it is extremely useful as an indirect test for
preclinical diagnosis. The South Hampshire flock is now
configured so that all normal sheep used are GG and all
heterozygotes AG. Since all affected animals are AA this
guarantees that only affected offspring are AA, carriers AG and
normal sheep GG in the next generation. The use of this marker
was tested against brain biopsy diagnoses on 213 affected and
heterozygous lambs over 4 years with 100% agreement, and it is
now used routinely for diagnosis in the South Hampshires.
The c.822G>A polymorphism was also analysed in the
Merino flock (n=74) to yield a LOD score of 7.83. No evidence
for recombination between this polymorphism and the disease
phenotype was detected (θ=0). Conversely, no linkage was
found between the c.822G>A polymorphism and the disease
phenotype in the Borderdale sheep thus excluding a disease
causing mutation in CLN6 or a gene nearby as the cause of the
NCL in these sheep. Affected Borderdale sheep possessed either
allele randomly, six out of 12 tested being AA, three being AG
and three GG.
A third allelic variant found at the end of the coding region, a
c.933_934insCT insertion predicted to lead to an extra tyrosine
at the C-terminal end of the putative protein (Fig. 1) followed by
a different termination triplet, TGA, is also unlikely to be a
disease causing mutation. The sequences reported for other
species all have an additional amino acid here and it is not
conserved (Fig. 1). The CT insertion has been observed in all
affected Merino and South Hampshire sheep, but was also
found in the BAC clone and was relatively common in the
Coopworth control animals sequenced, where five out of 24
alleles (12 animals) contained the insertion, three animals being
heterozygous and one homozygous for it.
A fourth allelic variant, c.56A>G, codes for an amino acid
substitution p.Gln19Arg (Fig. 1) but is not linked with the
disease phenotype. All 3 affected and 2 normal Merino sheep
sequenced were homozygous for the ‘A’ allele and are predicteden exons 4 and 6 yields transcripts retaining (249 bp) or lacking exon 5 (193 bp),
he exact lack of exon 5 in the smaller band (right panel). Arrows indicate the
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(Fig. 1). All five affected South Hampshire sheep sequenced
were homozygous for the G allele but so was a Borderdale
sheep and one out of two Coopworth controls. The G allele was
also found in the EST and the BAC.
PCR products amplified from cDNA using primers located
in exons 4 and 6 of the CLN6 gene yielded mixed sequences,
consistent with some template lacking exon 5. These two
transcripts were separated on agarose gels (Fig. 4) and
sequencing confirmed one retaining (249 bp) and one lacking
(193 bp) exon 5. Both transcripts were present in all sheep
tested, normal and affected South Hampshires and Merinos, and
Coopworth controls. PCRs of cDNA across the other exons,
1–3, 2–4, 3–5 and 5–7 gave single amplicons and continuously
unique sequences.
This exon 5 skipping leads to a frame-shift and a putative
truncated protein with a premature stop codon, 184 amino acids
versus 310 amino acids for the normal protein. The frame-shift
also changes the last 21 amino acids of the putative truncated
protein to the unusual sequence Vhpllpyplhvlqrllyshqs. Blast
searching for the protein containing motifs revealed no
homology to known sequences.
The absence of any mutations in the coding region of the
affected South Hampshires prompted a quantitative real time
PCR study to determine if CLN6 mRNA expression or stability
was affected in these sheep. Levels of CLN6 mRNA in affected
and carrier South Hampshire and control brains, livers and
muscle were normalised to glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) as the internal standard. Each splicing
variant was amplified separately by using primers spanning the
exon junctions, ex4–5F that sits on the exon 4–5 junction and
allows amplification of only the full length form and ex4–6R
reverse which anneals to the exon 4–6 junction and allows
amplification of only the splicing variant lacking exon 5. The
relative amounts of both transcripts detected in affected South
Hampshire brain and liver were less than 1/3 those of the control
sheep tissues (Fig. 5). Tissues from heterozygote South
Hampshires contained intermediate amounts. In contrast
affected and normal Merino tissues contained similar amounts
of both transcripts (Fig. 5).Fig. 5. The abundance of CLN6 mRNA in tissues of South Hampshire (SH) and Merin
real-time PCR. CLN6 means in the affected SH sheep (white bars, left and right pane
t-test) than the CLN6 means in the normal SH sheep (black bars, left and right panels
grey bars. However the CLN6 means in the affected Merino sheep (white bars, centr
sheep (black bars, centre panel) (n=3).4. Discussion
The full coding sequence for ovine CLN6 has been deter-
mined, a disease causing substitution mutation (c.184C>T)
recognised in the affected Australian Merino sheep, a disease
associated lowering of CLN6 transcripts found in the affected
New Zealand South Hampshire sheep and CLN6 excluded as
the locus responsible of the disease in the New Zealand
Borderdales.
Contrary to initial considerations the mutations responsible
for the CLN6 NCLs in Australian Merino and New Zealand
South Hampshires are not the same, despite the similarity of
clinical signs and pathology between the two forms
[10,12,36,46]. Several factors indicate that the c.184C>T
substitution found in exon 2 of the affected Merino sheep is
the disease causing mutation. Firstly, there is unambiguous
association between an amino acid substitution and the
disease phenotype. Secondly, the predicted major amino acid
change, a p.Arg62Cys substitution in the CLN6 protein
(Fig. 1), is very similar to a human disease causing substitution,
p.Arg62His [47]. Finally, no other possible disease causing
mutations were found in the coding regions and the normal
mRNA levels observed preclude abnormal transcription or
instability.
The same mutation does not appear in affected South
Hampshire sheep. The disease causing mutation in them has yet
to be determined but tight linkage to the c.822G>A
polymorphism indicates that it is in CLN6 or closely nearby.
The significant decrease in the relative amount of CLN6
transcripts in the affected animals strongly suggests down
regulation of the transcription of CLN6 or mRNA instability
(Fig. 5). This possibility is reinforced by the intermediate
transcript levels in the carriers.
With hindsight it is not surprising that the mutations in the
two sheep breeds are not the same. The two breeds have
relatively separate origins. Secondly, a number of different
mutations within human CLN6 lead to the same disease
phenotype. Originally it was thought that human CLN6 was
restricted to a narrow set of founder mutations in descendents
from European gypsies and Costa Ricans but it is now evidento normal and affected sheep. The amount of mRNA in tissues was quantified by
ls) are significantly less (n=3, *P=0.03; **P=0.0005; ***P=0.0074, Student's
). The intermediate CLN6 means in the heterozygous SH sheep are indicated by
e panel) are not significantly different to the CLN6 means in the control Merino
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mutations. The number of cases diagnosed, the number of
mutations described and the geographic distribution of cases has
increased rapidly since the discovery of the causative gene [47–
49]. So far 22 mutations have been identified in CLN6 in
families from 12 different countries (www.ucl.ac.uk/ncl), all
with a similar disease course.
There are also more than 20 variant late infantile NCL cases
where the mutations have eluded detection that may be caused
by mutations in CLN6, since genetic analysis is consistent with
linkage to the CLN6 locus (Mole, S.E., personal communica-
tion). These include a group of Roma Gypsy families used in the
original linkage analysis, in which two different haplotypes
segregate, suggesting two different mutations, neither of which
has been identified. These may be the most common disease-
causing mutation(s) of CLN6. There was evidence of alternative
splicing affecting exon 1 for one of these haplotypes (Mole, S.
E., personal communication). The human mutations not yet
identified may also disturb transcription or cause transcript
instability. Determining the mutation in affected South
Hampshire sheep will be an important step in understanding
the regulation of CLN6 and its role in NCL.
Full genomic sequencing of CLN6 in normal sheep and both
models is underway. Left to complete are the 5′ UTR, most of
intron 1, and part of intron 2. Sequencing of the 5′-untranslated
region is the most difficult. This end of the coding sequence has
a very high GC content and little is known about the 5′-
untranslated region of any species. A variable number of
pentameric repeats have been reported in a human family but it
is unclear if this polymorphism is disease associated [47]. Direct
BAC sequencing is being used to determine the normal ovine 5′
end.
The ovine gene organisation is very similar to that of human
CLN6 and there is a high degree of homology between species
along the whole coding length (Fig. 1). A notable feature is the
variation between species in the amino acids at the C terminal
end of the coded peptide (Fig. 1), indicating that this is not a
functionally important residue and supporting the concept that
the allelic c.933_934insCT insertion observed in some sheep,
which adds a tyrosine (Y), is unlikely to be of biological
importance.
Some human disease causing mutations have already been
found in introns 2, 4 and 5 [47–49]. The splicing excision of
exon 5 was discovered during cDNA sequencing but it is not
associated with disease. The C terminal sequence of the putative
shortened polypeptide Vhpllpyplhvlqrllyshqs is unusual, par-
ticularly the unique juxtaposition of amino acids around the
prolines and it is unlikely that this variant codes for a functional
product. No other splicing variants were uncovered suggesting
that alternative splicing is not an important functional feature of
CLN6.
Simple molecular tests for diagnosis are particularly valuable
and are now available for both the Merino and South Hampshire
diseases (Figs. 2 and 3). They allow the diagnosis of disease
status in these models at any age, which is invaluable for
preclinical and prenatal investigations. The advantages of the
sheep; clinical progression, neuroanatomy, neuropathology andphysiology that closely resembles humans, and easy care and
management, will continue to be exploited for pathology,
biochemistry and cell biology studies and therapeutic trials. The
Merino flock will be expanded to provide enough animals with
a known mutation for a full range of investigations. Linkage and
sequencing studies are underway to determine the lesion in the
Borderdales, which will then provide a sheep model of another
form of NCL.
Acknowledgements
This study was supported by the US National Institutes of
Health, NINDS grant NS40297 (DP, GK, NM), successive
grants from the Batten Disease Support and Research
Association (BDSRA), the University of Sydney Research
Grants Scheme, a F.H. Loxton scholarship (PH), a New Zealand
Neurological Foundation Philip Wrightson Fellowship (TF) and
a grant from Lysosomal Diseases New Zealand. We would like
to thank Donald Arthur and Bruce Sheat for their interest and
co-operation in establishing the Borderdale flock, and David J.
Palmer, Nigel Jay and Gretchen McGuire for expert technical
assistance.
References
[1] J.A. Rider, D.L. Rider, Thirty years of Batten disease research: present
status and future goals, Mol. Genet. Metab. 66 (1999) 231–233.
[2] M. Haltia, The neuronal ceroid-lipofuscinoses, J. Neuropathol. Exp.
Neurol. 62 (2003) 1–13.
[3] J. Tyynelä, Neuronal Ceroid-Lipofuscinosis, in: P. Saftig (Ed.), Lyso-
somes, Landes Bioscience, Georgetown, TX, U.S.A., 2004, pp. 82–99.
[4] H.H. Goebel, S.E. Mole, B.D. Lake (Eds.), Biomedical and Health
Research, The Neuronal ceroid lipofuscinoses (Batten Disease), vol. 33,
ISO Press, Amsterdam, 1999.
[5] E. Siintola, S. Partanen, P. Stromme, A. Haapanen, M. Haltia, J. Maehlen,
A-E. Lehesjoki, J. Tyynelä, Cathepsin D deficiency underlies congenital
human neuronal ceroid-lipofuscinosis, Brain 129 (2006) 1438–1445.
[6] J. Tyynelä, I. Sohar, D.E. Sleat, R.M. Gin, R.J. Donnelly, M. Baumann,
M. Haltia, P. Lobel, A mutation in the ovine cathepsin D gene causes a
congenital lysosomal storage disease with profound neurodegeneration,
EMBO J. 19 (2000) 2786–2792.
[7] T. Awano, M.L. Katz, D.P. O'Brien, J.F. Taylor, J. Evans, S. Khan,
I. Sohar, P. Lobel, G.S. Johnson, A mutation in the cathepsin D gene
(CTSD) in American Bulldogs with neuronal ceroid lipofuscinosis, Mol.
Genet. Metab. 87 (2005) 341–348.
[8] M. Koike, H. Nakanishi, P. Saftig, J. Ezaki, K. Isahara, Y. Ohsawa,
W. Schulz-Schaeffer, T. Watanabe, S. Waguri, S. Kametaka, M. Shibata,
K. Yamamoto, E. Kominami, C. Peters, K. von Figura, Y. Uchiyama,
Cathepsin D deficiency induces lysosomal storage with ceroid lipofuscin
in mouse CNS neurons, J. Neurosci. 20 (2000) 6898–6906.
[9] R.D. Jolly, D.M. West, Blindness in South Hampshire sheep: a neuronal
ceroid-lipofuscinosis, N. Z. Vet. J. 24 (1976) 123.
[10] R.D. Jolly, D.N. Palmer, The neuronal ceroid-lipofuscinoses (Batten
disease): comparative aspects, Neuropathol. Appl. Neurobiol. 21 (1995)
50–60.
[11] R.D. Jolly, R.D. Martinus, D.N. Palmer, Sheep and other animals with
ceroid-lipofuscinoses: their relevance to Batten disease, Am. J. Med.
Genet. 42 (1992) 609–614.
[12] I.G. Mayhew, R.D. Jolly, B.T. Pickett, P.M. Slack, Ceroid-lipofuscinosis
(Batten's disease): pathogenesis of blindness in the ovine model,
Neuropathol. Appl. Neurobiol. 11 (1985) 273–290.
[13] D.N. Palmer, R.D. Martinus, S.M. Cooper, G.G. Midwinter, J.C. Reid,
R.D. Jolly, Ovine ceroid-lipofuscinosis: The major lipopigment protein
905I. Tammen et al. / Biochimica et Biophysica Acta 1762 (2006) 898–905and the lipid-binding subunit of mitochondrial ATP synthase have the
same NH2-terminal sequence, J. Biol. Chem. 264 (1989) 5736–5740.
[14] I.M. Fearnley, J.E. Walker, R.D. Martinus, R.D. Jolly, K.B. Kirkland, G.J.
Shaw, D.N. Palmer, The sequence of the major protein stored in ovine
ceroid lipofuscinosis is identical with that of the dicyclohexylcarbodii-
mide-reactive proteolipid of mitochondrial ATP synthase, Biochem. J. 268
(1990) 751–758.
[15] D.N. Palmer, I.M. Fearnley, J.E. Walker, N.A. Hall, B.D. Lake, L.S. Wolfe,
M. Haltia, R.D. Martinus, R.D. Jolly, Mitochondrial ATP synthase subunit
c storage in the ceroid-lipofuscinoses (Batten disease), Am. J. Med. Genet.
42 (1992) 561–567.
[16] J. Tyynelä, J. Suopanki, P. Santavuori, M. Baumann, M. Haltia, Variant
late infantile neuronal ceroid-lipofuscinosis: pathology and biochemistry,
J. Neuropathol. Expt. Neurol. 56 (1997) 369–375.
[17] J. Tyynelä, D.N. Palmer, M. Baumann, M. Haltia, Storage of saposins A
and D in infantile neuronal ceroid-lipofuscinosis, FEBS Lett. 330 (1993)
8–12.
[18] J.R. Faust, J.S. Rodman, P.F. Daniel, J.F. Dice, R.T. Bronson, Two related
proteolipids and dolichol-linked oligosaccharides accumulate in motor
neuron degeneration mice (mnd/mnd), a model for neuronal ceroid
lipofuscinosis, J. Biol. Chem. 269 (1994) 10150–10155.
[19] E. Fossale, P. Wolf, J.A. Espinola, T. Lubicz-Nawrocka, A.M. Teed,
H. Gao, D. Rigamonti, E. Cattaneo, M.E. MacDonald, S.L. Cotman,
Membrane trafficking and mitochondrial abnormalities precede subunit c
deposition in a cerebellar cell model of juvenile neuronal ceroid lipofusci-
nosis, BMC Neurosci. 5 (2004) 57–69.
[20] C.A. Pardo, B.A. Rabin, D.N. Palmer, D.L. Price, Accumulation of the
adenosine triphosphate synthase subunit C in the mnd mutant mouse. A
model for neuronal ceroid lipofuscinosis, Am. J. Pathol. 144 (1994)
829–835.
[21] R.D. Jolly, D.N. Palmer, V.P. Studdert, R.H. Sutton, W.R. Kelly, N.
Koppang, G. Dahme, W.J. Hartley, J.S. Patterson, R.C. Riis, Canine
ceroid-lipofuscinoses: a review and classification, J. Small Anim. Pract. 35
(1994) 299–306.
[22] R.D. Martinus, P.A.W. Harper, R.D. Jolly, S.L. Bayliss, G.G. Midwater,
G.J. Shaw, D.N. Palmer, Bovine ceroid-lipofuscinosis (Batten's disease):
the major component stored is the DCCD-reactive proteolipid, subunit c,
of mitochondrial ATP synthase, Vet. Res. Commun. 15 (1991) 85–94.
[23] A. Url, B. Bauder, J. Thalhammer, N. Nowotny, J. Kolodziejek, N. Herout,
S. Furst, H. Weissenböck, Equine neuronal ceroid lipofuscinosis, Acta
Neuropathol. 101 (2001) 410–414.
[24] M.J. Oswald, D.N. Palmer, G.W. Kay, S.J.A. Shemilt, P. Rezaie, J.D.
Cooper, Glial activation spreads from specific cerebral foci and precedes
neurodegeneration in presymptomatic ovine neuronal ceroid lipofuscinosis
(CLN6), Neurobiol. Dis. 20 (2005) 49–63.
[25] G.W. Kay, D.N. Palmer, P. Rezaie, J.D. Cooper, Activation of non-
neuronal cells within the prenatal developing brain of sheep with neuronal
ceroid lipofuscinosis, Brain Pathol. 16 (2006) 110–116.
[26] C. Heine, J. Tyynelä, J.D. Cooper, D.N. Palmer, M. Elleder, A.
Kohlschütter, T. Braulke, Enhanced expression of manganese-dependent
superoxide dismutase in human and sheep CLN6 tissues, Biochem. J. 376
(2003) 369–376.
[27] W.J. Streit, R.E. Mrak, W.S.T. Griffin, Microglia and neuroinflammation: a
pathological perspective, J. Neuroinflam. 1 (2004) 14.
[28] G. Raivich, M. Bohatschek, C.U.A. Kloss, A. Werner, L.L. Jones, G.W.
Kreutzberg, Neuroglial activation repertoire in the injured brain: graded
response, molecular mechanisms and cues to physiological function, Brain
Res.: Brain Res. Rev. 30 (1999) 77–105.
[29] G. Stoll, S. Jander, The role of microglia and macrophages in the
pathophysiology of the CNS, Prog. Neurobiol. 58 (1999) 233–247.
[30] A. Minagar, P. Shapshak, R. Fujimura, R. Ownby, M. Heyes, C. Eisdorfer,
The role of macrophage/microglial and astrocytes in the pathogenesis of
three neurologic disorders: HIV-associated dementia, Alzheimer disease,
and multiple sclerosis, J. Neurol. Sci. 202 (2002) 13–23.[31] M.F. Broom, C. Zhou, J.E. Broom, K.J. Barwell, R.D. Jolly, D.F. Hill,
Ovine neuronal ceroid lipofuscinosis: a large animal model syntenic with
the human neuronal ceroid lipofuscinosis variant CLN6, J. Med. Genet. 35
(1998) 717–721.
[32] H. Gao, R.M. Boustany, J.A. Espinola, S.L. Cotman, L. Srinidhi, K.A.
Antonellis, T. Gillis, X. Qin, S. Liu, L.R. Donahue, R.T. Bronson, J.R.
Faust, D. Stout, J.L. Haines, T.J. Lerner, M.E. MacDonald, Mutations in a
novel CLN6-encoded transmembrane protein cause variant neuronal
ceroid lipofuscinosis in man and mouse, Am. J. Hum. Genet. 70 (2002)
324–335.
[33] R.B. Wheeler, J.D. Sharp, R.A. Schultz, J.M. Joslin, R.E. Williams, S.E.
Mole, The gene mutated in variant late-infantile neuronal ceroid
lipofuscinosis (CLN6) and in nclf mutant mice encodes a novel predicted
transmembrane protein, Am. J. Hum. Genet. 70 (2002) 537–542.
[34] C. Heine, B. Koch, S. Storch, A. Kohlschütter, D.N. Palmer, T. Braulke,
Defective endoplasmic reticulum-resident membrane protein CLN6 affects
lysosomal degradation of endocytosed arylsulfatase A, J. Biol. Chem. 279
(2004) 22347–22352.
[35] S.E. Mole, G. Michaux, S. Codlin, R.B. Wheeler, J.D. Sharp, D.F. Cutler,
CLN6, which is associated with a lysosomal storage disease, is an
endoplasmic reticulum protein, Exp. Cell Res 298 (2004) 399–406.
[36] R.W. Cook, R.D. Jolly, D.N. Palmer, I. Tammen, M.F. Broom, R.
McKinnon, Neuronal ceroid lipofuscinosis in Merino sheep, Aust. Vet. J.
80 (2002) 292–297.
[37] I. Tammen, R.W. Cook, F.W. Nicholas, H.W. Raadsma, Neuronal ceroid
lipofuscinosis in Australian Merino sheep: a new animal model, Eur. J.
Paediatr. Neurol. 5 (2001) 37–41.
[38] R.D. Jolly, D.G. Arthur, G.W. Kay, D.N. Palmer, Neuronal ceroid-
lipofuscinosis in Borderdale sheep, N. Z. Vet. J. 50 (2002) 199–202.
[39] L.R. Dickson, I. Dopfmer, R.R. Dalefield, R.J. Graydon, R.D. Jolly, A
method of cerebro-cortical biopsy in lambs, N. Z. Vet. J. 37 (1989) 21–22.
[40] D. Vaiman, A. Billault, K. Tabet-Aoul, L. Schibler, D. Vilette, A. Oustry-
Vaiman, C. Soravito, E.P. Cribiu, Construction and characterization of a
sheep BAC library of three genome equivalents, Mamm. Genome 10
(1999) 585–587.
[41] W.S. Oetting, H.K. Lee, D.J. Flanders, G.L. Wiesner, T.A. Sellers, R.A.
King, Linkage analysis with multiplexed short tandem repeat polymorph-
isms using infrared fluorescence and M13 tailed primers, Genomics 30
(1995) 450–458.
[42] S.C. Romer, K.A. Brumbaugh, V. Boveia, M. Jensen, J. Gardener,
Simultaneous bi-directional cycle sequencing, 9th International Genome
Sequencing and Analysis Conference, Hilton Head, SC, 1997.
[43] C. Burge, S. Karlin, Prediction of complete gene structures in human
genomic DNA, J. Mol. Biol. 25 (1997) 78–94.
[44] K.B. Nicholas, H.B. Nicholas Jr., D.W. Deerfield II, GeneDoc: analysis
and visualization of genetic variation, Embnet News 4 (1997) 14.
[45] P. Green, Construction and comparison of chromosome 21 radiation
hybrid and linkage maps using Cri-Map, Cytogenet. Cell Genet. 59 (1992)
122–124.
[46] R.J. Graydon, R.D. Jolly, Ceroid-lipofuscinosis (Batten's disease):
sequential electrophysiologic and pathologic changes in the retina of the
ovine model, Invest. Ophthalmol. Visual Sci. 25 (1984) 294–301.
[47] J.D. Sharp, R.B. Wheeler, K.A. Parker, R.M. Gardiner, R.E. Williams, S.E.
Mole, Spectrum of CLN6 mutations in variant late infantile neuronal
ceroid lipofuscinosis, Hum. Mutat. 22 (2003) 35–42.
[48] C.A. Teixeira, J. Espinola, L. Huo, J. Kohlschütter, D.-A. Persaud Sawin,
B. Minassian, C.J.P. Bessa, A. Guimarães, D.A. Stephan, M.C. Sá
Miranda, M.E. MacDonald, M.G. Ribeiro, R.-M.N. Boustany, Novel
mutations in the CLN6 gene causing a variant late infantile neuronal ceroid
lipofuscinosis, Hum. Mutat. 21 (2003) 502–508.
[49] E. Siintola, M. Topcu, A. Kohlschütter, T. Salonen, T. Joensuu, A.K.
Anttonen, A.-E. Lehesjoki, Two novel CLN6 mutations in variant late-
infantile neuronal ceroid lipofuscinosis patients of Turkish origin, Clin.
Genet. 68 (2005) 167–173.
